The key difference: one operation or two?

For most patients comparing cartilage repair options, the most immediate practical question is straightforward: how many operations does this involve? STACI (Single Treatment Autologous Chondrocyte Implantation) answers that question with one. Cartilage is harvested, processed, and implanted within a single uninterrupted theatre session, with a dedicated laboratory team working alongside the surgeon in the operating room — no waiting, no second admission.

Conventional ACI and MACI both require two separate procedures. In the first, a small cartilage biopsy is taken arthroscopically. The harvested cells are then sent to an external laboratory, where they are cultured and expanded over roughly six to eight weeks. Only then does the patient return for a second, open operation in which the expanded cells are implanted into the defect.

MACT (matrix-induced ACI, more widely known as MACI) is sometimes assumed to be simpler than first-generation ACI because it represents a newer approach — but this is a misconception worth correcting. MACI's genuine advance was in delivery method: at the second operation, cells are seeded onto a collagen membrane rather than sealed under a periosteal patch. The two-stage sequence of biopsy, laboratory culture, and reimplantation is unchanged. MACI is fundamentally two-stage.

Despite this structural difference in how they are delivered, all three techniques share the same clinical target: a focal, full-thickness cartilage defect in a knee that is otherwise mechanically sound and free from diffuse arthritis.

What happens inside a STACI procedure

Once the defect is exposed, the procedure moves through four rapid steps — all within the same anaesthetic. A small cartilage sample is taken from a non-load-bearing area of the knee. Rather than being dispatched to an external laboratory for weeks of cell expansion, the tissue is handed immediately to a specialist preparation team working inside the operating theatre, who mince it into fine chips. Those chips are combined with autologous bone-marrow mononucleated cells (MNCs) — drawn from the patient's own marrow during the same session — or with platelet-rich plasma. The resulting biological mixture is seeded onto a scaffold and implanted into the defect before the operation ends.

Marrow-derived cells release growth signals that appear to stimulate the minced chondrocytes to proliferate and produce cartilage matrix — a mechanism known as paracrine signalling. This is thought to offset the smaller chondrocyte numbers available from a single-session harvest compared with weeks of external culture. A 2025 systematic review covering 48 studies, including four clinical trials, found synergistic cartilage formation in all 27 experiments that compared co-implantation of chondrocytes with a second cell type against chondrocytes implanted alone, lending biological support to the single-stage co-implantation rationale.

It is worth being clear about what that evidence does and does not show. The review supports the mechanism; it does not establish that STACI produces superior clinical outcomes to ACI or MACI. Head-to-head randomised trials between single-stage and two-stage approaches have not yet been published, and long-term survivorship data remain limited.

What the clinical evidence currently shows

The most robust clinical data available comes from a 2020 prospective multicenter study of 40 patients treated with freshly isolated autologous chondrocytes and bone-marrow mononucleated cells on a PolyActive scaffold. Successful lesion filling — defined as at least 67% MRI coverage — was achieved in all 40 patients at three months and maintained in all 32 available at 24 months. Pain scores improved significantly from three months onwards, and biopsies taken from 31 patients confirmed hyaline-like repair tissue in 22 cases. These are meaningful signals: consistent fill, sustained pain relief, and tissue quality at biopsy are appropriate indicators of early biological success.

The picture extends, though does not yet deepen substantially, with a 2024 case series reporting clinical outcomes up to five years in 16 patients treated on a hyaluronan scaffold. Five-year follow-up in a single-stage cohort is valuable — it represents the longest published horizon for this approach — but a series of 16 patients remains small and observational.

The most important gap is structural: no randomised controlled trial has directly compared STACI with ACI or MACI. ACI and MACI carry multi-decade survivorship records, with published series extending well past ten years. STACI's evidence base, though encouraging, is not yet at that scale. Patients and clinicians considering single-stage treatment should weigh that difference clearly — not as a reason to dismiss the approach, but as an honest reflection of where the evidence currently stands.

The hidden costs of waiting between operations

Completing the two-stage pathway is less straightforward than its name suggests. A 2024 cohort study of 71 patients who underwent MACI phase-one biopsy found that only 35% progressed to second-stage implantation. Larger lesion size and age 26 or over were independent predictors of requiring both stages — yet even among those patients, a substantial proportion never reached reimplantation. For them, the biopsy was the entire intervention.

The inter-stage interval carries a further biological hazard. Time between biopsy and reimplantation has been associated with expansion in both the number and size of chondral lesions, meaning the defect treated at implantation may be larger and more complex than the one assessed at harvest. STACI removes this variable by completing harvest and implantation within a single anaesthetic.

Longer-term outcomes from the established two-stage pathway also merit consideration. At 60 months after cartilage repair with microfracture or MACI, 44.4% of patients showed intralesional bony overgrowth, significantly associated with elevated T2 values in the opposing articular cartilage (p=0.004) — an imaging marker of potential stress in the facing surface. This is a complication of the repair environment rather than of the waiting period specifically, but it is a meaningful long-term signal when weighing the overall risk profile of established approaches.

On cost, the two-stage structure accumulates charges by design: two theatre sessions, two anaesthetic fees, and external laboratory processing all precede the repair itself. STACI is estimated at £11,797–£12,500 partly because it collapses those components into one session. Individual pricing varies by setting and defect complexity, but the structural cost difference between one admission and two is real for most pathways.

Which patients suit which approach

Age, defect size, and prior procedures are the three parameters specialists weigh most carefully when selecting between STACI, ACI, and MACI.

Age

STACI is generally positioned for biologically younger patients — typically under 40 — where the intraoperative co-implantation approach is thought to be most effective. ACI and MACI carry their longest published evidence in adults up to the mid-50s. These are guiding parameters rather than fixed cut-offs: individual biology and activity level both contribute alongside a patient's calendar age.

Defect size

The clearest size-related evidence anchor is the SUMMIT trial, which found that microfracture produced significantly worse pain and function scores than cell-based repair at both two and five years for defects of 3 cm² or larger — the threshold above which marrow stimulation cannot supply sufficient biological material for durable repair. STACI, ACI, and MACI are all intended for lesions broadly in this range; for smaller defects (roughly under 2 cm²), other approaches may be more appropriate.

Prior procedures

A history of microfracture can reduce the success rate of subsequent ACI, and some evidence suggests a similar effect on related cell-based approaches. Patients who have already undergone marrow-stimulation surgery should raise this when seeking a specialist opinion, as it may influence which technique is most suitable.

Selecting the right approach depends on how these factors — age, lesion size, and previous interventions — combine in each individual, which is why specialist assessment is the essential next step.

What remains unknown and how to find a specialist

Honest technique selection depends on a specialist who routinely offers more than one option. STACI carries genuine biological rationale and encouraging early outcomes; it also sits at an earlier stage of evidential maturity than ACI or MACI, and patients considering it deserve a clear account of that asymmetry rather than a comparison framed around any single approach.

Cartilage repair specialists experienced in both single-stage and two-stage chondrocyte-based repair are listed across the UK on Search MSK — the region and specialty filters help identify those whose practice covers the full range of options. Two questions this article's evidence equips a patient to raise: first, whether the centre routinely performs both single-stage and two-stage procedures, since a surgeon working predominantly with one approach may not weigh the alternatives objectively; and second, what imaging follow-up the centre commits to at two and five years, given that MRI-confirmed lesion fill and repair-tissue quality are more meaningful markers of long-term durability than early pain and function scores alone.